Compare AbCellera Biologics Inc (ABCL) vs Nucor Corporation (NUE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Nucor Corporation — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Nucor Corporation trades at $225.79 (market cap $51.79B). The key difference: Nucor Corporation is far larger — about 22× AbCellera Biologics Inc's market cap, and Nucor Corporation pays a 0.98% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | NUE | |
|---|---|---|
Market Cap | $2.35B | $51.79B |
Sector | Health | Basic Materials |
52-Week High | $8.12 | $266.35 |
52-Week Low | $2.78 | $131.78 |
Enterprise Value | $1.99B | $56.44B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Nucor (NUE) trades at $227.42, up 3.02% over the past day, with a bearish technical signal despite recent earnings beats. The stock shows mixed sentiment with 59% analyst buy ratings but faces declining revenue and net income from 2022 peaks. Recent developments include a joint venture to support AI power infrastructure and a consistent dividend history, with Q2 2026 EPS guidance projecting growth.
Outlook remains cautiously optimistic due to strong analyst targets averaging $260.75 and operational expansions, though risks include steel demand volatility and compressed profit margins. The stock's valuation at a P/E of 22.21 appears reasonable if earnings rebound as projected in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
